Ultragenyx Pharmaceutical Inc. Stock
Ultragenyx Pharmaceutical Inc. shows a slight decrease today, losing -€0.400 (-0.990%) compared to yesterday.
We see a rather positive sentiment for Ultragenyx Pharmaceutical Inc. with 17 Buy predictions and 1 Sell predictions.
Based on the current price of 39.8 € the target price of 84 € shows a potential of 111.06% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.990% | -1.463% | -6.481% | 4.663% | -7.339% | -55.604% | -33.781% |
| Ironwood Pharmaceuticals | 6.210% | -3.333% | -8.805% | -22.043% | -28.922% | -21.622% | - |
| Sage Therapeutics Inc. | -3.520% | -3.667% | -23.728% | -70.207% | -38.925% | -81.156% | - |
| Novocure Ltd | 2.120% | 15.965% | -1.196% | -77.601% | -7.391% | -92.217% | - |
Comments
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat